NAD+ Research Protocols: Dosing, Routes, and Study Design

NAD+ (nicotinamide adenine dinucleotide) presents a unique challenge in preclinical research design: it is not a peptide, its pharmacokinetics differ substantially from injectable peptides, and the choice between direct NAD+ injection, NMN, and NR has significant implications for what you are actually measuring. Researchers approaching NAD+ for the first time frequently find that the compound behaves differently from other longevity compounds in the catalog — shorter half-life, route-dependent tissue access, and a metabolism that intersects with multiple enzymatic pathways that each require their own controls.

This guide focuses specifically on the practical research protocol side: how different forms of NAD+ replenishment are delivered in published studies, what doses and routes have been used in murine models, how to prepare and store research-grade NAD+, and which study design considerations are most commonly missed. For mechanism and longevity biology background, see the companion article 'NAD+: Cellular Energy, Sirtuins, and Longevity Research.'

Why Route of Administration Changes Everything for NAD+

Most research peptides behave predictably across routes — SC, IP, and IV differ in Tmax and bioavailability but the compound itself reaches the bloodstream intact. NAD+ is different. Orally administered free NAD+ is largely degraded by intestinal phosphodiesterases before absorption; what reaches the circulation is primarily nicotinamide (NAM) — a breakdown product with its own biological activity, including sirtuin inhibition at high concentrations.

This is why oral NAD+ supplementation research has shifted to using stable NAD+ precursors — NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) — which enter cells via nucleoside transporters or dedicated NMN transporters and are converted to NAD+ intracellularly by NRK and NMNAT enzymes. Direct IP or IV injection of free NAD+ bypasses gastrointestinal degradation entirely, delivering intact NAD+ to plasma where it can be taken up by tissues.

Injectable NAD+: What the Published Literature Uses

Intraperitoneal injection of free NAD+ is the most common route in acute and subacute murine studies. The compound is rapidly absorbed from the peritoneal cavity via portal venous and lymphatic drainage, achieving high plasma concentrations within 15–30 minutes. The primary limitation is the short plasma half-life of free NAD+ — approximately 1.5–2 hours in rodents — which means IP dosing typically uses once-daily or twice-daily protocols for chronic studies.

Key published rodent doses for injectable NAD+ and NAD+ precursors:

• NAD+ IP (acute/subacute): 250–500 mg/kg in neuroprotection models (ischemia, TBI); Klaidman et al. and Belenky-Brenner data; single bolus or twice-daily
• NMN IP (chronic metabolic): 500 mg/kg/day in Gomes et al. 2013 Cell (aged mice, 1 week); demonstrated mitochondrial reversal of muscle aging phenotype
• NMN IP (metabolic dysregulation): 500 mg/kg/day in Yoshino et al. 2011 Cell Metabolism (HFD-induced obese mice); improved insulin sensitivity and restored NAMPT expression
• NR oral gavage: 400 mg/kg/day in Canto et al. 2012 Cell Metabolism (HFD mice); improved oxidative metabolism, protected against metabolic syndrome phenotype
• NMN oral gavage: 300–500 mg/kg/day across multiple mouse aging and metabolic studies; Slc12a8 intestinal transporter mediates NMN uptake (Grozio 2019)
• NAD+ IV (human equivalent reference): Pencina et al. 2023 Nature Aging used 1g IV in humans; 5× greater 1-hr blood NAD+ elevation vs NMN 600mg oral or NR 1g oral

For researchers using injectable free NAD+ (CAS 53-84-9), these doses represent the published preclinical framework. Note that 500 mg/kg/day in mice corresponds to a human equivalent dose of approximately 40 mg/kg using the FDA BSA conversion (Km factor 12.3) — far above the 250–500 mg/day doses used in human clinical trials, underscoring the well-documented translation gap in NAD+ preclinical-to-clinical dose extrapolation.

Reconstitution Protocol for Research-Grade NAD+

NAD+ has specific reconstitution requirements that differ from most research peptides. Importantly, bacteriostatic water (BAC water containing 0.9% benzyl alcohol) should NOT be used for NAD+ reconstitution. The benzyl alcohol preservative can oxidize NAD+ over time, degrading the compound during storage. Use sterile saline (0.9% NaCl) or PBS (pH 7.4) instead.

• Solvent: Sterile saline (0.9% NaCl) or phosphate-buffered saline (pH 7.4) — NOT bacteriostatic water
• Concentration: For IP dosing at 500 mg/kg in mice, a 50 mg/mL stock allows dosing at 10 mL/kg body weight; for 100 mg vials, add 2.0 mL sterile saline
• Mixing: Gentle inversion or swirling only — NAD+ dissolves quickly; no vortexing required
• Color: Reconstituted NAD+ is colorless to very pale yellow; significant yellowing suggests oxidation, discard
• Preparation timing: Prepare fresh for each dosing session when possible; reconstituted NAD+ degrades more rapidly than most peptides
• pH check: NAD+ solution should be neutral (pH 6.5–7.5); strongly acidic or basic conditions accelerate hydrolysis at the glycosidic bond

Storage Protocol and Light Sensitivity

NAD+ is significantly more sensitive to light and oxidation than most research peptides. The nicotinamide ring system is susceptible to photodegradation, and NAD+ can be oxidized to NADH or hydrolyzed to AMP + NMN under adverse conditions. Proper storage is essential for maintaining compound integrity over multi-week study periods.

• Lyophilized (vial): Store at −20°C in original amber glass vial. Lyophilized NAD+ is stable for 12–18 months under these conditions.
• Amber vials essential: ALWAYS store NAD+ (lyophilized or reconstituted) in amber glass or opaque containers. Clear glass vials with foil wrapping are an acceptable substitute.
• Light exposure: Even brief bench exposure to direct fluorescent lab lighting can degrade reconstituted NAD+ within hours. Work under dim lighting or wrap working solutions in foil.
• Reconstituted (short-term): Store at 4°C in amber vial, protected from light. Use within 24–48 hours. Do not freeze reconstituted NAD+ — repeat freeze-thaw cycles cause rapid degradation.
• Reconstituted (longer-term): If multi-day dosing is required, aliquot immediately after reconstitution into single-use amber vials; freeze aliquots at −80°C; thaw each aliquot once on day of use.
• Quality check: Measure UV absorbance at 340 nm (the peak of NADH, indicating reduction/contamination) or at 259 nm (NAD+ absorption peak); a significant 340/259 ratio shift indicates oxidation.

Sirtuin Activation Assay Endpoints

When designing an NAD+ study with sirtuin activation as the primary endpoint, selecting the right assay matters significantly. Several options exist, each with trade-offs:

• NAD+/NADH ratio (enzymatic cycling assay): The most direct measure of cellular NAD+ status. Requires tissue homogenate; commercial kits (Abcam ab65348, Sigma MAK037) use enzymatic cycling. Samples must be collected rapidly and stored at −80°C to prevent ex vivo enzymatic changes.
• SIRT1 deacetylase activity (fluorescent substrate assay): Using Fluor de Lys SIRT1 substrate or equivalent; measures functional SIRT1 activity in tissue lysates. More informative than NAD+ alone — shows downstream enzymatic consequences of NAD+ level changes.
• Acetylated/total PGC-1alpha ratio (IP/western): Quantifies SIRT1 target deacetylation; a useful proxy for SIRT1 activity in vivo without requiring cell-free assay conditions. Requires co-immunoprecipitation with anti-PGC-1alpha followed by pan-acetyl-lysine western.
• Mitochondrial content markers: mtDNA copy number by qPCR (mt-16S vs nuclear reference gene); TOMM20, VDAC, or porin by western; citrate synthase activity in tissue homogenate. All downstream of NAD+/sirtuin/PGC-1alpha axis.
• Seahorse XF: Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) from isolated mitochondria or intact cells; most functionally informative endpoint for mitochondrial biogenesis/function claims.

NAMPT Inhibition Controls

Because the NAMPT salvage pathway accounts for 85–90% of intracellular NAD+ synthesis, NAMPT inhibitors are invaluable controls for confirming that observed effects are NAD+-dependent. FK866 (also known as APO866 or Daporinad) is the most widely used NAMPT inhibitor in research; it depletes intracellular NAD+ within 24–48 hours at 10–50 nM (in vitro) or 10 mg/kg IP (in vivo in mice).

Including an FK866 group serves two purposes: (1) it confirms that your readout is sensitive to NAD+ depletion (validating the assay), and (2) it defines the baseline for rescued vs. depleted NAD+ status, making your supplementation data more interpretable. For rescue experiments, co-treatment with FK866 + NAD+/NMN/NR should restore the endpoint if NAD+ elevation is genuinely responsible for the effect.

• FK866 in vitro: 10–50 nM for 24–48 hrs in most cell lines; depletes NAD+ by 80–95%; verify by enzymatic cycling assay before adding experimental compounds
• FK866 in vivo (mice): 10 mg/kg IP twice daily × 4 days (from Hasmann & Schemainda 2003 Cancer Research); produces significant NAD+ depletion in tumors and liver; dose may need optimization for non-tumor tissue endpoints
• Alternative NAMPT inhibitors: GMX1778, CHS-828; different potencies and tissue distributions; FK866 remains most published
• Recovery time: After FK866 withdrawal, NAD+ levels in most tissues recover within 48–72 hours via de novo and Preiss-Handler pathways; plan your rescue experiment timing accordingly

Four Critical Research Design Considerations

• NAM contamination in vehicle controls: Both NMN and NR are metabolized to NAM as an intermediate. High-dose studies can produce significant plasma NAM levels, which inhibit sirtuins at concentrations above 200 µM. Include a vehicle group receiving equimolar NAM at the dose your precursor generates to control for this; if NAM-vehicle shows similar effects to your treatment, the effect may be NAM-mediated rather than NAD+-mediated.
• Circadian timing of dosing and collection: NAD+ levels and NAMPT expression oscillate with a ~24-hour circadian rhythm — peak NAD+ typically occurs during the active phase (nighttime in mice). Dosing and tissue collection at random times dramatically increases variance. Fix collection to the same ZT (Zeitgeber time) across all groups; standardize dosing to the same circadian phase (ZT12 ± 1 hour is most commonly used in published protocols).
• Age of animals: NAD+ replenishment effects are most pronounced in aged animals (22+ months in mice), where baseline NAD+ is 50–70% depleted compared to young adult. Young adult mice (8–12 weeks) often show minimal phenotypic response because their salvage pathway capacity is sufficient. If your scientific question relates to aging biology, use genuinely aged animals — the compound will behave very differently than in young mice.
• Tissue-specific interpretation: Blood/plasma NAD+ is the most accessible measurement but is not representative of muscle, liver, brain, or heart NAD+. Each tissue has distinct expression of NRK enzymes (for NR uptake), Slc12a8 (for NMN uptake), and NMNAT isoforms. If your endpoint is in muscle or brain, verify that your delivery route and dose actually elevate NAD+ in that tissue — do not assume blood NAD+ elevation predicts tissue NAD+ elevation.

Combining NAD+ with Other Longevity Compounds

NAD+ is frequently studied in combination with other longevity research compounds. The most mechanistically grounded combinations from the published literature are:

• NAD+ + MOTS-c: Non-overlapping mechanisms (NAD+/sirtuin axis vs AMPK/AICAR folate cycle). MOTS-c activates AMPK independently of NAD+, but AMPK activation increases NAMPT expression, potentially creating a positive feedback loop that amplifies NAD+ replenishment. The Lee 2015 Cell Metabolism MOTS-c data and Gomes 2013 NMN data suggest complementarity.
• NAD+ + SS-31: SS-31 targets cardiolipin directly to stabilize respiratory supercomplex architecture; NAD+ provides substrate for ETC via NADH at Complex I. Both ultimately target mitochondrial ETC function but via non-competing mechanisms. Combination logic is strongest in cardiac I/R and skeletal muscle aging models.
• NAD+ + Epitalon: NAD+/SIRT1 deacetylates and increases accessibility of the BDNF promoter region; Epitalon activates TERT. Together they address two distinct hallmarks of cellular aging (metabolic/mitochondrial + telomere maintenance). No published head-to-head data exist but the combination is increasingly used in longevity research protocols.
• NAD+ + GHK-Cu: GHK-Cu activates Nrf2 antioxidant pathway; NAD+ fuels SIRT3-mediated SOD2 activation. Both reduce mitochondrial ROS burden via different mechanisms. Low theoretical risk of receptor/pathway competition.

Practical Checklist for NAD+ Research Protocol Setup

• Solvent selection: Sterile saline or PBS — never BAC water. Verify pH 6.5–7.5.
• Amber vial: Always. Foil-wrap working solutions during dosing.
• Fresh preparation: Reconstitute on day of dosing. If multi-day, freeze aliquots at −80°C in single-use volumes.
• Circadian control: Fix dosing and collection to the same ZT. Document precisely.
• NAMPT inhibitor group: Include FK866 arm to validate NAD+-dependence of endpoints.
• NAM vehicle control: If using NMN or NR, include equimolar NAM control.
• Tissue vs blood measurement: If claiming tissue-level effects, collect tissue at necropsy — do not rely on blood NAD+ as proxy.
• Animal age matching: Match groups precisely; NAD+ metabolism changes rapidly with age. Use aged cohorts if the research question involves aging phenotypes.

Nexphoria supplies NAD+ (nicotinamide adenine dinucleotide, CAS 53-84-9) at ≥99% purity by HPLC, identity confirmed by mass spectrometry, lot-specific COA available. Lyophilized, 100 mg per vial, stored at −20°C. For combination longevity stack research, see the related compound pages for MOTS-c, SS-31, Epitalon, and GHK-Cu.

All products sold by Nexphoria are for research use only. Not for human consumption. Not FDA-approved for any clinical application. Researchers are responsible for compliance with institutional protocols, applicable laws, and regulatory requirements in their jurisdiction.